2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Hemophilia, Platelet Disorders, Thrombotic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4756 Platelet mitochondrial bioenergetics are altered and associated with inflammatory signaling in hemophilia A with and without arthropathy

Anuj Raj Kaul, Gowtham Annarapu, PhD2, Venkat Ramakrishna Ungarala3, Angelina Kendi4, Craig Seaman, MD5, Nicoletta C Machin, DO, MS6, Sruti Shiva, PhD7
1 Pittsburgh Heart, Lung, Blood Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
2 Pittsburgh Heart, Lung, Blood Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
3 Pittsburgh Heart, Lung, Blood Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
4 Pittsburgh Heart, Lung, Blood Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
5 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University of Pittsburgh Division of Classical Hematology, Pittsburgh, Pennsylvania, United States
6 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University of Pittsburgh Division of Classical Hematology, Pittsburgh, Pennsylvania, United States
7 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, Pittsburgh Heart, Lung, Blood Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States, University of Pittsburgh Division of Classical Hematology, Pittsburgh, Pennsylvania, United States

Background: Patients with Hemophilia A show significant variability in bleeding phenotype and arthropathy pathogenesis that is not completely explained by Factor VIII (FVIII) deficiency.  Recent studies suggest that alterations to platelet function and reactivity potentially contribute to differences in patient phenotype.  Platelets contain metabolically active mitochondria which, through bioenergetics and oxidant production, regulate platelet function including activation and secretion.  However, platelet mitochondrial function and its contribution to vascular pathology in hemophilia A remains unexplored.  We hypothesized that platelet mitochondrial function is altered in hemophilia A and contributes to inflammatory pathways associated with hemophilic arthropathy.

Methods: We isolated platelets from the blood of hemophilia A patients with moderate disease (N=15; 11 males, 4 females; Aged 21-43 years old), hemophilia A patients with diagnosed arthropathy (N= 5; males; aged 24-40), and age/race matched healthy controls (N=15; 10 males, 5 females).  We measured platelet mitochondrial function, including bioenergetic profile, membrane potential and mitochondrial reactive oxygen species (mtROS) production in all subjects along with platelet surface p-selectin expression and plasma levels of inflammatory mediators.  To directly assess the impact of FVIII deficiency and joint injury on platelet mitochondrial dysfunction, identical measures were made in a murine model of hemophilia A. Platelet and mitochondrial dysfunction were measured in wildtype, FVIII knockout mice (FVIII-KO) and FVIII-KO two weeks after sub-patellar needle puncture to model early arthropathy.

Results: Patients with hemophilia A showed a significant change in platelet mitochondrial bioenergetics characterized by decreased basal respiratory rate and increased proton leak, indicative of decreased efficiency of ATP production.  This bioenergetic alteration was accompanied by a statistically significant increase in mtROS production. Notably, hemophilia A patients with arthropathy showed a more pronounced decrease in basal respiration and greater enhancement in mtROS production compared to hemophilia A patients without arthropathy. These alterations were recapitulated in a murine model in vivo. Platelets from FVIII-KO mice showed elevated mtROS production and this was further exacerbated in FVIII-KO mice following sub-patellar joint injury. Across human subjects, altered platelet bioenergetics were significantly associated with an increase in platelet surface p-selectin (Pearson’s r = 0.39; p<0.01) as well as plasma interleukin-1β levels (r= 0.42; p<0.01).

Conclusions:   These data provide the first evidence of basal mitochondrial bioenergetic dysfunction in hemophilia A patients, which are further exacerbated by hemophilic arthropathy. Our findings suggest that this mitochondrial dysfunction is linked to platelet activation and systemic inflammatory signaling. Ongoing studies are testing whether mitochondrial dysfunction mechanistically underlies platelet activation and inflammatory signaling, which will establish whether platelet mitochondria represent a novel therapeutic target to attenuate the pathogenesis of hemophilic arthropathy.

Anuj Raj Kaul: No relevant conflicts of interest to declare.